Resumo

CASTRO, I. J. et al. Study on the adverse reactions related to paclitaxel and docetaxel infusion. Farm Hosp. [online]. 2013, vol.37, n.2, pp.88-94. ISSN 2171-8695.  https://dx.doi.org/10.7399/FH.2013.37.2.374.

Objective: To determine the incidence of paclitaxel and docetaxel infusion-associated reactions, and the likely causes that may trigger them. Method: Cohort study of the paclitaxel and docetaxel infusions carried out at a tertiary hospital from July of 2010 to December of 2011 (18 months). For each infusion, the clinical data and the drug-related data were recorded. When a reaction occurred during the infusion the following data were specified: type, severity, if treatment withdrawal was needed. The clinical charts and treatment orders were reviewed. The follow-up of the infusions were done by contacting the day-care hospital nurses. A descriptive study was done for the most relevant variables included in the follow-up and we analyzed if any of them could have had an influence on the occurrence of the reactions. Results: During the study period, 357 paclitaxel and docetaxel Infusions were administered to 92 patients: mean age 61.4 years (SD 11.1), 50.0% were female. 9 infusion reactions affecting 8 patients occurred, all of them caused by docetaxel (χ² = 8.3, p = 0.004); 14.5% of the patients receiving it, and always during the first or second treatment cycle. The variables significantly associated to the occurrence of the reaction were: lung cancer (p<0.005), docetaxel-cisplatin regime (p<0.005), receiving the drug as first line (p = 0.021), and non-advanced disease (p = 0.014). Conclusions: At our hospital, docetaxel is the taxane that has provoked the most frequent safety problems during the infusion.

Palavras-chave : Paclitaxel; Docetaxel; Hypersensitivity reaction.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )